Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDFNASDAQ:CRVONASDAQ:IMABNASDAQ:INBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$3.65-0.3%$3.20$2.01▼$5.64$243.49M1.521.20 million shs993,961 shsCRVOCervoMed$5.87+3.9%$7.80$1.80▼$20.63$49.17M-0.751.34 million shs151,547 shsIMABI-Mab$2.09-2.8%$1.67$0.60▼$3.08$175.57M1.4391,784 shs351,396 shsINBXInhibrx Biosciences$18.35+12.4%$13.45$10.80▼$18.41$236.39M-0.0496,094 shs280,697 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology0.00%+16.06%-5.77%+35.91%+65.43%CRVOCervoMed0.00%-5.45%-24.93%-41.39%-63.10%IMABI-Mab0.00%-13.23%-8.98%+259.68%+39.38%INBXInhibrx Biosciences0.00%+12.86%+16.99%+35.71%+26.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.669 of 5 stars3.41.00.00.02.70.00.6CRVOCervoMed3.2672 of 5 stars3.44.00.00.03.31.70.6IMABI-Mab2.8797 of 5 stars3.73.00.00.02.21.70.6INBXInhibrx Biosciences0.992 of 5 stars0.01.00.04.60.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.80Moderate Buy$9.88170.55% UpsideCRVOCervoMed 2.89Moderate Buy$27.63370.61% UpsideIMABI-Mab 3.33Buy$6.00187.08% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest CRVO, IMAB, CRDF, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $5.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$680K357.11N/AN/A$1.86 per share1.96CRVOCervoMedN/AN/AN/AN/A$4.50 per shareN/AIMABI-Mab$3.89M43.87N/AN/A$2.47 per share0.85INBXInhibrx Biosciences$200K1,328.54$131.07 per share0.14$9.23 per share1.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)CRVOCervoMed-$16.29M-$2.18N/AN/AN/A-200.57%-44.07%-40.65%8/8/2025 (Estimated)IMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.16N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)Latest CRVO, IMAB, CRDF, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/A5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A6.226.22CRVOCervoMedN/A9.789.78IMABI-MabN/A22.3522.35INBXInhibrx Biosciences1.045.125.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%CRVOCervoMed25.15%IMABI-Mab38.38%INBXInhibrx Biosciences82.46%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%CRVOCervoMed35.40%IMABI-Mab22.10%INBXInhibrx BiosciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableCRVOCervoMed48.70 million5.62 millionNot OptionableIMABI-Mab38081.66 million63.61 millionOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableCRVO, IMAB, CRDF, and INBX HeadlinesRecent News About These CompaniesINBX - Inhibrx Biosciences Inc Executives - MorningstarJuly 2, 2025 | morningstar.comMInhibrx Biosciences, Inc. (INBX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comInhibrx Biosciences Inc (INBX) - Investing.comJune 25, 2025 | investing.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial ResultsMay 15, 2025 | finanznachrichten.deInhibrx Reports First Quarter 2025 Financial ResultsMay 14, 2025 | prnewswire.comInhibrx Biosciences reshuffles leadership, appoints new CSO and PresidentApril 3, 2025 | investing.comInhibrx announces leadership changes as co-founder departsApril 2, 2025 | thepharmaletter.comTInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentApril 1, 2025 | prnewswire.comInhibrx Biosciences Full Year 2024 Earnings: Beats ExpectationsMarch 19, 2025 | finance.yahoo.comInhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 18, 2025 | finanznachrichten.deInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 17, 2025 | prnewswire.comWhen the Price of (INBX) Talks, People ListenFebruary 12, 2025 | news.stocktradersdaily.comNWhy Inhibrx Biosciences, Inc.’s (INBX) Stock Is Up 10.07%January 31, 2025 | aaii.comAInhibrx's SWOT analysis: oncology biotech stock faces pivotal year aheadJanuary 22, 2025 | msn.comInhibrx Biosciences Inc (INBX) Gets a Hold from JMP SecuritiesJanuary 22, 2025 | markets.businessinsider.comInhibrx reports promising ozekibart trial resultsJanuary 22, 2025 | msn.comInhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal CancerJanuary 21, 2025 | prnewswire.comHow to Take Advantage of moves in (INBX)January 20, 2025 | news.stocktradersdaily.comNOxford Finance Provides Up to $150MM Term Loan to Inhibrx BiosciencesJanuary 14, 2025 | abladvisor.comAInhibrx Biosciences Announces Loan Agreement with Oxford FinanceJanuary 13, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVO, IMAB, CRDF, and INBX Company DescriptionsCardiff Oncology NASDAQ:CRDF$3.65 -0.01 (-0.27%) Closing price 04:00 PM EasternExtended Trading$3.70 +0.04 (+1.23%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.CervoMed NASDAQ:CRVO$5.87 +0.22 (+3.89%) Closing price 04:00 PM EasternExtended Trading$5.85 -0.02 (-0.32%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.I-Mab NASDAQ:IMAB$2.09 -0.06 (-2.79%) Closing price 04:00 PM EasternExtended Trading$2.11 +0.02 (+0.96%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Inhibrx Biosciences NASDAQ:INBX$18.35 +2.02 (+12.37%) Closing price 04:00 PM EasternExtended Trading$18.34 -0.01 (-0.03%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
